These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer. D'Amico AV J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901 [No Abstract] [Full Text] [Related]
5. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Lopez S; Simon JM; Mazeron JJ Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304 [TBL] [Abstract][Full Text] [Related]
6. The androgen receptor for the radiation oncologist. Quero L; Rozet F; Beuzeboc P; Hennequin C Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704 [TBL] [Abstract][Full Text] [Related]
7. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy. Lee EC; Tenniswood MP J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758 [TBL] [Abstract][Full Text] [Related]
8. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. Koontz BF; Lee WR Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767 [TBL] [Abstract][Full Text] [Related]
9. [Hormonal treatment in cancer of the prostate]. Boccon-Gibod L Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774 [No Abstract] [Full Text] [Related]
11. Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan. Sasaki T; Nakamura K; Ogawa K; Onishi H; Okamoto A; Koizumi M; Shioyama Y; Mitsumori M; Teshima T; BJU Int; 2009 Nov; 104(10):1462-6. PubMed ID: 19522869 [TBL] [Abstract][Full Text] [Related]
12. The benefits of early androgen blockade. Maroni PD; Crawford ED Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):317-29. PubMed ID: 18471789 [TBL] [Abstract][Full Text] [Related]
13. Hormonal therapy for prostate cancer. Rosenberg AG; von Eschenbach AC Semin Surg Oncol; 1990; 6(2):71-6. PubMed ID: 2180044 [TBL] [Abstract][Full Text] [Related]
14. Primary androgen deprivation therapy in men with prostate cancer. Laufman L JAMA; 2009 Jan; 301(1):35; author reply 35. PubMed ID: 19126809 [No Abstract] [Full Text] [Related]
16. Complete androgen blockade for the treatment of prostate cancer. Labrie F; Dupont A; Belanger A Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740 [No Abstract] [Full Text] [Related]
17. [Disseminated carcinoma of the prostate: monotherapy or complete androgenic blockade?]. González Martín M; Gómez Veiga F; Alvarez Castelo L Arch Esp Urol; 1997 Dec; 50(10):1067-76. PubMed ID: 9494195 [TBL] [Abstract][Full Text] [Related]
18. The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy. Soloway MS Prog Clin Biol Res; 1990; 350():141-8. PubMed ID: 2201040 [No Abstract] [Full Text] [Related]
19. Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist. Boudreaux KJ; Chang SS BJU Int; 2008 Mar; 101(6):671-4. PubMed ID: 18070172 [No Abstract] [Full Text] [Related]
20. [Hormonal receptors and other procedures for predicting clinical response in cancer of the prostate]. Habib FK; Chisholm GD Arch Esp Urol; 1984 Dec; 37 Suppl 2():751-9. PubMed ID: 6085672 [No Abstract] [Full Text] [Related] [Next] [New Search]